Nasdaq grts.

EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Nasdaq grts. Things To Know About Nasdaq grts.

Track Gritstone Bio Inc (GRTS) Stock Price, Quote, latest community messages, chart, news and other stock related information.Gritstone bio (NASDAQ:GRTS) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock?We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types.Aug 4, 2022 · Second Quarter 2022 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $159.2 million as of June 30, 2022, compared to $223.5 million as of December 31, 2021 ...

Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious …Web

Jan 9, 2022 · Insiders seem to have made the most of their holdings by selling US$221k worth of Gritstone bio, Inc. (NASDAQ:GRTS) stock at an average sell price of US$22.10 during the past year. The company's ... 16 พ.ค. 2566 ... HC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy Recommendation ... Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated ...

EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the …WebThere are 196 funds or institutions reporting positions in Gritstone Bio. This is an increase of 42 owner (s) or 27.27% in the last quarter. Average portfolio weight of all funds dedicated to GRTS ...About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.EMERYVILLE, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...

Aug 10, 2022 · Celebrations may be in order for Gritstone bio, Inc. (NASDAQ:GRTS) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have ...

Find the latest Insider Activity data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.

Stock analysis for Gritstone bio Inc (GRTS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.About Latest Pre-Market Trades. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. 16 พ.ค. 2566 ... HC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy Recommendation ... Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated ...Management criteria checks 3/4. Gritstone bio's CEO is Andrew Allen, appointed in Aug 2015, has a tenure of 8.25 years. total yearly compensation is $2.68M, comprised of 23.2% salary and 76.8% bonuses, including company stock and options. directly owns 1.6% of the company’s shares, worth $2.07M. The average tenure of the management team and ...EMERYVILLE, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.Aug 4, 2022 · Second Quarter 2022 Financial Results. Cash, cash equivalents, marketable securities and restricted cash were $159.2 million as of June 30, 2022, compared to $223.5 million as of December 31, 2021 ... Find the latest dividend history for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.Gritstone bio ( NASDAQ: GRTS) is developing a second-generation covid vaccine that is designed to work in two ways; first, it will generate a robust neutralizing antibodies response, and second ...EMERYVILLE, Calif., VANCOUVER, British Columbia, and BASEL, Switzerland, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to ...9 มี.ค. 2566 ... (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today reported financial results ...marketbeat.com - July 5 at 5:00 AM. Gritstone bio (NASDAQ:GRTS) shareholders have endured a 70% loss from investing in the stock three years ago. finance.yahoo.com - July 4 at 10:02 AM. Board Member at Gritstone Bio Acquires Company Stock Options Worth 51,800 Shares. benzinga.com - June 22 at 11:42 PM.

Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares stood at 0.86 million during the last session, with the company’s beta value hitting 0.59. At the close of trading, the stock’s price was $1.88, to imply an increase of 2.73% or $0.05 in intraday trading. The GRTS share’s 52-week high remains $4.05, putting it -115.43% down since that peak ...Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

If you want to know who really controls Gritstone bio, Inc. (NASDAQ:GRTS), then you'll have to look at the makeup of its share registry. We can see that retail investors own the lion's share in the company with 43% ownership. ... NasdaqGS:GRTS Earnings and Revenue Growth October 6th 2023. Our data indicates that hedge funds own 16% of …(NASDAQ: GRTS) Gritstone Bio's forecast annual revenue growth rate of 76.39% is forecast to beat the US Biotechnology industry's average forecast revenue growth ...16 พ.ค. 2566 ... HC Wainwright & Co. Reiterates Gritstone Bio (GRTS) Buy Recommendation ... Fintel reports that on May 15, 2023, HC Wainwright & Co. reiterated ...16 ต.ค. 2566 ... The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ... GRTS + ...Follow. EMERYVILLE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...The 36-month beta value for GRTS is also noteworthy at 0.44. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”. The average price estimated by analysts for GRTS is $10.40, which is $9.08 above than the current price.While there are scores of intriguing bargains in biotech right now, Gritstone bio (GRTS 3.79%) and Sorrento Therapeutics (SRNE.Q 8.33%) both have the potential to deliver life-changing gains for ...

May 31, 2022 · EMERYVILLE, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ...

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced ...

Verizon, Walgreens, and 4 Other Stocks. The S&P 500's Best Payouts: 7%+ Dividend Yields. Get the latest GRTS (GRTS) real-time quote, historical performance, charts, and other financial... May 6, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the …WebEMERYVILLE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today ...Mar 8, 2022 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious …WebGritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.GRTS Latest After Hours Trades. Select time range to see more trades: Last 100 Trades. After Hours Time (ET) After Hours Price. After Hours Share Volume. 18:30:18. $2.47. 9.WebEric Enderson. November 21, 2023. In the last trading session, 1.28 million Gritstone Bio Inc (NASDAQ:GRTS) shares changed hands as the company’s beta touched 0.47. With the company’s per share price at $1.32 changed hands at -$0.04 or -2.94% during last session, the market valuation stood at $125.85M. GRTS’s last price was a discount ...Find the latest Financials data for Gritstone bio, Inc. Common Stock (GRTS) at Nasdaq.com.WebGritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases.

Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone ...Sep 27, 2023 · EMERYVILLE, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS ), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, announced today that it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) to conduct a Phase 2b comparative study ... A. Gritstone Bio ( GRTS) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 8, 2023 for Q3 and the Actual Revenue was $1.6M, which ...Instagram:https://instagram. how much is gold barchwy newsgoogle ipo stock pricebill.ocm During the recent session, Gritstone Bio Inc (NASDAQ:GRTS)’s traded shares were 0.46 million, with the beta value of the company hitting 0.56. At the last check today, the stock’s price was $1.46, reflecting an intraday loss of -6.73% or -$0.1. The 52-week high for the GRTS share is $4.05, that ...Jul 15, 2021 · Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. hyg etf dividendvteb dividend yield Gritstone Bio Inc (NASDAQ:GRTS) trade information. Sporting -3.50% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 11/13/23 when the GRTS stock price touched $1.38 or saw a rise of 25.61%. Year-to-date, Gritstone Bio Inc shares have moved -60.00%, while the 5-day ...EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today ... ten square games Gritstone bio's $785 million collaboration for HIV therapies has quantified the value of EDGE more than any Wall Street analyst could ever do. Gilead has already given GRTS $30 million upfront and ...Dec 1, 2023 · The following insider purchased GRTS shares in the last 24 months: Vassiliki Economides ($22,800.00). How much insider buying is happening at Gritstone bio? Insiders have purchased a total of 12,000 GRTS shares in the last 24 months for a total of $22,800.00 bought.